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Genetic heterogeneity; majority of cases autosomal 
dominant, occasionally with variable expression 
(incomplete dominance) manifesting as mild anemia in 
transmitting parent; some cases apparently autosomal 
recessive, not linked to 19q. 
Clinics 
Phenotype and clinics 
- Chronic constitutional are generative anemia with 
absent or decreased red cell precursors in bone marrow;  
- Macrocytosis, elevated fetal hemoglobin, increased 
red cell adenosine deaminase;  
- Physical abnormalities in 30% of DBA cases 
including craniofacial and thumb abnormalities, atrial 
or ventricular septal defects, short stature, mild 
retardation, etc. 
Neoplastic risk 
- Hematologic malignancy: in 2.5% of all reported 
cases of DBA; primarily ANLL with no FAB 
preference but also ALL, Hodgkin's disease; 
- Solid tumors include carcinoma of liver, stomach, 
osteogenic sarcoma; 
- Age of malignancy onset from 2 to 43 years; 
- Disease-related and treatment-related factors, i.e.
allosensitization and iron overload, contribute to 
malignancy. 
Treatment 
Corticosteroids, transfusion, bone marrow transplant. 
Evolution 
Some patients enter remission, with or without 
corticosteroid therapy. 
Prognosis 
Median survival: 38 years. 





Description: Ribosomal protein S19; ribosomal 
proteins are a major component of cellular proteins; 
their function(s), aside from being part of the ribosome, 
are unknown. 
Mutations 
Germinal: Mutations in RPS 19 identified in DBA 
patients include non-sense, frameshift, splice site and 
missense mutations; three patients had disease-
associated chromosomal abnormalities in DBA region, 
t(X;19), t(8;19), microdeletion 19q. 
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